Samsung Biologics Enters The Pharmaceutical Supply Chain Initiative

Samsung Biologics, a leading global contract development and manufacturing organization (CDMO), has made history by becoming the first Korean CDMO to join the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner. This initiative comprises pharmaceutical and healthcare companies committed to excellence in safety, environmental responsibility, and social outcomes throughout the global healthcare value chain.

By joining the PSCI, Samsung Biologics pledges to uphold principles that focus on five key areas of responsible business practices: Ethics, Labor, Health & Safety, Environment and Management Systems. The company views this partnership as a crucial step toward enhancing its commitment to sustainable growth and bolstering its Environmental, Social, and Governance (ESG) management efforts. As part of its strategy to decarbonize and create more resilient supply chains, Samsung Biologics is actively collaborating with suppliers within the Sustainable Market Initiative's Health Systems Task Force as a leader in the Supply Chains Working Group.